192 related articles for article (PubMed ID: 31923082)
1. A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
Bristow RE; Chang J; Villanueva C; Ziogas A; Vieira VM
Obstet Gynecol; 2020 Feb; 135(2):328-339. PubMed ID: 31923082
[TBL] [Abstract][Full Text] [Related]
2. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
Galvan-Turner VB; Chang J; Ziogas A; Bristow RE
Gynecol Oncol; 2015 Dec; 139(3):495-9. PubMed ID: 26387962
[TBL] [Abstract][Full Text] [Related]
3. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
Obstet Gynecol; 2015 Apr; 125(4):833-842. PubMed ID: 25751200
[TBL] [Abstract][Full Text] [Related]
4. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
[TBL] [Abstract][Full Text] [Related]
5. Association of Hospital Volume With Racial and Ethnic Disparities in Locally Advanced Cervical Cancer Treatment.
Uppal S; Chapman C; Spencer RJ; Jolly S; Maturen K; Rauh-Hain JA; delCarmen MG; Rice LW
Obstet Gynecol; 2017 Feb; 129(2):295-304. PubMed ID: 28079775
[TBL] [Abstract][Full Text] [Related]
6. Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California.
Pfaendler KS; Chang J; Ziogas A; Bristow RE; Penner KR
Obstet Gynecol; 2018 May; 131(5):899-908. PubMed ID: 29630020
[TBL] [Abstract][Full Text] [Related]
7. Factors that influence minority use of high-volume hospitals for colorectal cancer care.
Huang LC; Tran TB; Ma Y; Ngo JV; Rhoads KF
Dis Colon Rectum; 2015 May; 58(5):526-32. PubMed ID: 25850840
[TBL] [Abstract][Full Text] [Related]
8. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease.
Bristow RE; Chang J; Ziogas A; Randall LM; Anton-Culver H
Gynecol Oncol; 2014 Feb; 132(2):403-10. PubMed ID: 24361578
[TBL] [Abstract][Full Text] [Related]
9. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.
Bristow RE; Chang J; Ziogas A; Anton-Culver H; Vieira VM
Gynecol Oncol; 2014 Jul; 134(1):60-7. PubMed ID: 24680770
[TBL] [Abstract][Full Text] [Related]
10. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
[TBL] [Abstract][Full Text] [Related]
11. Adherence to treatment guidelines for ovarian cancer as a measure of quality care.
Bristow RE; Chang J; Ziogas A; Anton-Culver H
Obstet Gynecol; 2013 Jun; 121(6):1226-1234. PubMed ID: 23812456
[TBL] [Abstract][Full Text] [Related]
12. Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
Hari A; Chang J; Villanueva C; Ziogas A; Vieira V; Bristow RE
Gynecol Oncol; 2024 Feb; 184():123-131. PubMed ID: 38309029
[TBL] [Abstract][Full Text] [Related]
13. Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment.
Kaspers M; Llamocca E; Quick A; Dholakia J; Salani R; Felix AS
Am J Obstet Gynecol; 2020 Sep; 223(3):398.e1-398.e18. PubMed ID: 32142825
[TBL] [Abstract][Full Text] [Related]
14. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Aviki EM; Lavery JA; Roche KL; Cowan R; Dessources K; Basaran D; Green AK; Aghajanian CA; O'Cearbhaill R; Jewell EL; Leitao MM; Gardner GJ; Abu-Rustum NR; Sabbatini P; Bach PB
Gynecol Oncol; 2020 Nov; 159(2):418-425. PubMed ID: 32814642
[TBL] [Abstract][Full Text] [Related]
15. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.
Bristow RE; Powell MA; Al-Hammadi N; Chen L; Miller JP; Roland PY; Mutch DG; Cliby WA
J Natl Cancer Inst; 2013 Jun; 105(11):823-32. PubMed ID: 23539755
[TBL] [Abstract][Full Text] [Related]
16. Hospital Readmission as a Poor Measure of Quality in Ovarian Cancer Surgery.
Uppal S; Spencer RJ; Rice LW; Del Carmen MG; Reynolds RK; Griggs JJ
Obstet Gynecol; 2018 Jul; 132(1):126-136. PubMed ID: 29889756
[TBL] [Abstract][Full Text] [Related]
17. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for laryngeal cancer.
Swegal WC; Herbert RJ; Eisele DW; Chang J; Bristow RE; Gourin CG
Laryngoscope; 2020 Mar; 130(3):672-678. PubMed ID: 31169916
[TBL] [Abstract][Full Text] [Related]
18. Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN).
Jochum F; De Rozario T; Lecointre L; Faller E; Boisrame T; Dabi Y; Lavoué V; Coutant C; Touboul C; Bolze PA; Bricou A; Canlorbe G; Collinet P; Huchon C; Bendifallah S; Ouldamer L; Mezzadri M; Querleu D; Akladios C
Int J Gynecol Cancer; 2021 Nov; 31(11):1443-1452. PubMed ID: 34607855
[TBL] [Abstract][Full Text] [Related]
19. Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
Chen F; Bailey CE; Alvarez RD; Shu XO; Zheng W
Gynecol Oncol; 2021 Jan; 160(1):10-15. PubMed ID: 33208254
[TBL] [Abstract][Full Text] [Related]
20. Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
Barber EL; Dusetzina SB; Stitzenberg KB; Rossi EC; Gehrig PA; Boggess JF; Garrett JM
Gynecol Oncol; 2017 Jun; 145(3):500-507. PubMed ID: 28366545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
